
Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

